US judgement in anti-CD20 Mab suit favours GSK's Arzerra: Genentech/Biogen to appeal
This article was originally published in Scrip
Executive Summary
US Judge Roger Benitez of the US District Court for the Southern District of California has entered a judgement in favour of GlaxoSmithKline pertaining to its anti-CD20 monoclonal antibody Arzerra (obatumumab) in a patent infringement case brought against the company in March 2010 by Genentech and Biogen Idec. The ruling concerns claim construction, and not the merits of the case, and the interpretation of the patent claims are appealable.